Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA YOUNG
2024-519655-28-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Apr 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of tamoxifen, letrozole, anastrozole, exemestane, goserelin and 7 more in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Invasive Breast Cancer Free Survival. Planned start Apr 2026; status: authorised.
02
Drugs
tamoxifenletrozoleanastrozoleexemestanegoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-519655-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519655-28-00.